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Background: Oropharyngeal mucositis (OM) is one of the main side-effects of oncological therapy. There is no 
treatment to prevent its occurrence, but some zinc-based therapies have been proven to help in decreasing its in-
tensity. The objective of this study was to determine the effect of zinc in OM in children with acute leukemia in 
the early stages of oncological treatment.
Material and Methods: This quasi-experimental study evaluated OM in 2 groups (control group: conventional 
hospital management, and experimental group: administration of 50 mg of zinc gluconate daily plus conventional 
hospital management). OM severity was recorded at a two-month follow-up.
Results: Forty-nine patients (26 in the control group and 23 in the experimental group) were included. The mean 
age of the patients was 11.1 ± 2.7 years; 65.3% had a diagnosis of pre-B acute lymphoblastic leukemia. The inci-
dences of OM in the control group and the experimental group were 46.2% and 26.1%, respectively, but the differ-
ence was not significant. Based on a negative binomial regression model, females had, on average, 1.5 more days 
with OM (p = 0.002), and patients assigned to the experimental group had, on average, 2 less days with OM than 
the control group (p = 0.001). The pain score was higher in the control group (p = 0.0009), as was the mean score 
on the WHO scale (p = 0.0012).
Conclusions: Zinc facilitated a reduction in the severity and duration of OM; further studies focusing on children 
are needed to confirm the effects of this trace element.
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Introduction
The main oncological treatments in case of children 
include chemotherapy, radiotherapy, and hematopoi-
etic stem cell transplantation (HSCT). Chemotherapy 
has a cytotoxic effect that eradicates malignant cells 
without discriminating against tissues with high cell 
division rates, such as the oral and gastrointestinal epi-
thelium (1-5). It can also cause complications such as 
myelosuppression, hepatic or renal disorders and oro-
pharyngeal mucositis (OM) (6). OM is defined as er-
ythema and edema of the mucosa with progression to 
ulcers. Patients who also present with neutropenia and 
thrombocytopenia have an increased risk of oral bleed-
ing and infections, which can lead to septicemia (2,7-9). 
OM involves pain, difficulty in swallowing and speak-
ing, malnutrition, functional status deterioration, longer 
hospital stay, increased economic costs and decreased 
quality of life (3,4,7,8,10-13). In the pathophysiology of 
OM, 5 phases have been described in which a variety 
of cells are involved (12-14). DNA damage in epithelial 
basal cells causes keratinocyte growth factor loss. The 
production of reactive oxygen species (ROS) activates 
nuclear transcription factor kappa B, which upregulates 
tumor necrosis factor-α, IL-6 and IL-1 and leads to the 
apoptosis of fibroblasts and endothelial cells, thereby 
causing epithelial lesions. Also, bacteria activate mac-
rophages, thus increasing the production of proinflam-
matory cytokines; subsequently, epithelial proliferation 
occurs until healing (10,11,14-16).
OM usually occurs between the 5th and 10th days after 
chemotherapy, resolving between days 7 and 14, given 
bone marrow suppression and infections do not occur 
(5,11,15), which is likely because the immune system of 
these patients is not effective at fighting infections (16). 
Previous studies have reported that 80% of patients 
undergoing radiotherapy suffer from OM; this figure 
increases to 90–100% in case of simultaneous chemo-
therapy, while it occurs in 20-80% of patients undergo-
ing chemotherapy solely. In the latter case, the rate can 
increase to more than 90% in children under 12 years of 
age, and in those using HSCT, the OM occurrence rate 
can be >75% (1,6,10,11,13,15,17,18). There are different 
OM grades. The most widely used evaluation scale for 
defining OM severity is that of the World Health Or-
ganization (WHO), which classifies OM into 5 grades 
(0-4) (2,15,19).
Several studies suggest that the occurrence of OM is 
mainly associated with cytotoxic type and patient char-
acteristics, being a frequent and difficult-to-resolve 
complication, despite the development of different ther-
apies (3). The Multinational Association of Supportive 
Care in Cancer/International Society of Oral Oncology 
(MASCC/ISOO) has indicated that oral care (brushing 
and flossing) has a beneficial effect in the form of de-
creased oral bacteria (10,15,19). Cheng et al. reported 
the effectiveness of oral care in children, demonstrating 
a reduction in the incidence of OM (20). Low-level la-
ser therapy has also been recommended in this context; 
however, it requires specialized equipment and train-
ing, and in children, cooperation is necessary (10,12). 
Topical ice application (cryotherapy) in the oral mucosa 
induces vasoconstriction and decreases exposure to the 
cytostatic agents, mainly 5-fluorouracil and melphalan; 
however, evidence of the benefits in pediatric patients is 
weak due to variances in chemotherapy type and treat-
ment adherence, while results for methotrexate and eto-
poside are not conclusive (10-12,15).
Morphine or doxepin rinses have also been useful for 
pain (9,10). Anesthetic solutions with diphenhydramine, 
viscous lidocaine, bismuth subsalicylate, and cortico-
steroids are alternatives, but no significant improve-
ment has been observed as a result of their use (11,15). 
Palifermin (keratinocyte growth factor-1) supports cell 
proliferation and helps in the prevention of OM; how-
ever, its efficacy and toxicity have not been demonstrat-
ed in children (9-12,18,19). Zinc is an antioxidant trace 
element essential for tissue repair, immune and anti-
inflammatory functions and resistance to infections 
(9,17,18,21,22). It is a cofactor for DNA synthesis and 
important in cell proliferation (18,23) and may increase 
the gastrointestinal epithelial barrier function, thus de-
creasing cell death and detachment (3,23). For the above 
reasons, it can reduce the incidence and severity of OM 
during chemotherapy (3). The MASCC/ISOO suggests 
using zinc in oral cancer therapies (10,19). The recom-
mended doses in children and adolescents range from 
10 to 15 mg/day. However, for therapeutic purposes, the 
dose can be increased to 22.5 mg of elemental zinc/100 
mg if administered as zinc sulfate, or to 30 mg or 80 mg 
elemental zinc/100 mg if administered as zinc acetate or 
zinc oxide, respectively (9). The objective of this study 
was to determine the effect of zinc in OM in children 
with acute leukemia in the early stages of oncological 
treatment.
Material and Methods 
This quasi-experimental study included all patients 
aged 8 to 16 years with a recent diagnosis of acute lym-
phoblastic leukemia (ALL) or acute myeloblastic leuke-
mia (AML) who began their first oncological treatment 
at the National Pediatrics Institute (Instituto Nacional 
de Pediatría - INP) from 2016 to 2018. Patients who had 
previously undergone oncological treatment and showed 
psychomotor delays were excluded. Parents who agreed 
to participate signed an Informed Consent (IC) form, 
and children below 12 years of age signed an Informed 
Assent form. Children above 12 years of age were also 
asked to sign the IC form together with their parents.
All patients and parents voluntarily agreed to par-
ticipate in the study. We instructed them to read and 
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first-generation antihistamine). The experimental group 
received the treatment that the hospital provided and 
50 mg of zinc gluconate daily, equivalent to 7 mg of 
elemental zinc, a dose similar to that recommended in 
children. Zinc gluconate (zinc bound to gluconic acid) 
was chosen to decrease the irritating effect on the gas-
tric mucosa. Zinc gluconate is an over-the-counter food 
supplement that does not require a prescription, so it 
was not necessary to register the study with the federal 
commission for protection against health risks. Both 
groups were instructed to rinse with baking soda after 
each meal, ~40 seconds.
The most important outcome variable was OM sever-
ity (using the WHO scale) and days with OM (from the 
time when OM was detected to recovery of the oral epi-
thelium). OM severity was evaluated in artificial light, 
with all physical protection barriers in place, by 2 ex-
aminers who had been previously trained and standard-
ized (weighted Kappa coefficient = 0.72). In addition, 
the other variables analyzed were sex, age, diagnosis, 
neutropenia, chemotherapy protocol, type of chemo-
therapy, oral hygiene and oral pain.
All materials were given to each of the participants. To 
verify response and adherence to treatment, cards were 
made for each group, and the number of zinc tablets and the 
consumption of materials for each group were monitored.
Statistical analysis. The qualitative data are presented as 
absolute numbers and percentages, while the quantita-
tive data are presented as the mean and standard devia-
tion (SD). Fisher’s exact test, chi-squared test, Student’s 
t-test, and analysis of variance (two-way ANOVA) were 
used to compare the groups with respect to OM grade 
and the VAS for oral pain. To evaluate the association 
between days with OM and the assigned group, a mul-
tivariate negative binomial regression model was used, 
adjusting for sex, age, neutropenia, diagnosis, chemo-
therapy, use of methotrexate and oral hygiene. The data 
were analyzed with STATA version 13.0.
we explain all procedures, and we indicated that they 
could withdraw from a follow-up at any time during the 
study, without any impact on their medical treatment. 
The study was approved by the INP research and eth-
ics committee. The sample size was the total popula-
tion available. Because the recruitment was slow due 
to the inclusion criteria and having a research period of 
two years, the researchers decided to perform an inter-
mediate analysis. The treatment allocation was done in 
blocks using sealed envelopes to have a balance in the 
number of participants in each group. The allocation of 
the group in sealed envelopes was carried out to identify 
and separate the effects of the treatments from the rest 
of the factors that affect the dependent variable.
The initial evaluation was performed before the patients 
started chemotherapy; Subsequently, evaluations were 
carried out every three days until they had completed 
51 days of chemotherapy. With a total of 17 evaluations 
in each group, each evaluation included a data collec-
tion sheet that recorded crucial information such as the 
evaluation number, sex, age, diagnosis, level of neutro-
penia, chemotherapy protocol, use of methotrexate, oral 
hygiene (using the O'Leary index), oral pain (using a 
linear visual analogue scale (VAS), where 0 = no pain 
and 10 = maximum pain), day of onset of OM, days 
with OM and evaluation of the severity of OM with 
the WHO scale. Both groups were trained in the proper 
techniques for brushing their teeth and rinsing their 
mouth (Table 1); all participants were asked to report 
any adverse reactions.
Table 1 describes the intervention by group. The control 
group received the treatment that the hospital provided, 
and if OM was present, rinses with Philadelphia solution 
were indicated (in this study, the solution was prepared 
as a mixture of 30 ml of aluminum-hydroxide-based 
antacid (3.7 g), magnesium hydroxide (4.0 g), 30% si-
methicone emulsion equivalent to 0.5 g of dimethicone, 
vehicle, qs for 100 ml and 30 ml of diphenhydramine, a 
CONTROL GROUP  EXPERIMENTAL GROUP
1 Dental treatment before or at the beginning of 
treatment, if necessary. 
1  Dental treatment before or at the beginning of 
treatment, if necessary. 
2  Gentle dental brushing with soft bristle brush. 2  Gentle dental brushing with soft bristle brush. 
3  Rinsing mouth with baking soda after each meal, 
~40 seconds. 
3  Rinsing mouth with baking soda after each meal, 
~40 seconds. 
4  Dental plaque control (O’Leary index) at time 0 
and at each check-up. 
4  Dental plaque control (O’Leary index) at time 0 and 
at each check-up. 
5  Evaluation of pain using a visual analog scale. 5  Evaluation of pain using a visual analog scale. 
6  When presenting with OM: Rinsing mouth with 
Philadelphia solution, 15 minutes before each meal
6  When presenting with OM: Rinsing mouth with 
Philadelphia solution, 15 minutes before each meal
7  Once daily: Zinc supplement (50 mg tablets), every 
morning after a meal 
Table 1: Description of the intervention in each study group.
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Results
The study included 61 patients, out of which 52 were 
divided into two groups according to the inclusion cri-
teria and there were three losses during the follow-up 
(Fig. 1). In the 49 patients, the mean age was 11.1 ± 2.7 
years. Of these, 59.2% were male, and 65.3% were diag-
nosed with pre-B ALL. In the baseline comparison, the 
groups did not show significant differences in sex, age, 
diagnosis, neutropenia, chemotherapy protocol or oral 
hygiene (Table 2).
During follow-up, a greater number of days with OM 
(14.2 ± 21.1 vs. 5.1 ± 11.2, p = 0.072) and a higher inci-
dence of OM (46.2% vs. 26.1%, p= 0.146) were observed 
in the control group compared with the experimental 
group; however, the differences were not significant 
(Table 3). We used a negative binomial regression mod-
el for days with OM (Table 4).
The experimental group had an average of 2 less days 
with OM than the control group (p = 0.001), and girls 
had an average of 1.5 more days with OM than boys 
(p = 0.002). With regard to the type of chemotherapy 
protocol, patients with 7+3+2, 7+3 and ADE had, on 
average, 1.5 less days with OM than patients with 
other protocols (p = 0.046). The mean OM severity 
and mean oral pain scores for the groups were signifi-
cantly different (F = 10.56, p = 0.0012 and F = 11.12, 
p = 0.0009, respectively). As shown in Fig. 2 and Fig. 
3, patients who received zinc had lower OM sever-
ity and associated pain, particularly between days 18 
and 39.
Characteristic Control group Experimental group Both groups P value
Number 26 23 49
Sex 
 Female 9 (34.6%) 11 (47.8%) 20 (40.8%) 0.348
 Male 17 (65.4%) 12 (52.2%) 29 (59.2%)
 Age, years 10.5 ± 0.6 11.7 ± 2.8 11.1 ± 2.7 0.101
 Diagnosis 
 Pre-B ALL 16 (61.5%) 16 (69.6%) 32 (65.3%)
 AML M0 4 (15.4%) 2 (8.7%) 6 (12.2%)
 AML M3 0 (0%) 1 (4.3%) 1 (2%)
 Pro-B ALL 4 (15.4%) 4 (17.4%) 8 (16.3%)
 ALL M2 1 (3.8%) 0 (0%) 1 (2%)
 Biphenotypic ALL 1 (3.8%) 0 (0%) 1 (2%) 0.822
 Neutropenia 
No neutropenia (>1500/μL) 13 (50%) 9 (39.1%) 22 (44.9%)
Mild (1000 to 1500/μL) 4 (15.4%) 1 (4.3%) 5 (10.2%)
Moderate (500 to 1000/μL) 4 (15.4%) 8 (34.8%) 12 (24.5%)
Severe (<500/μL) 5 (19.2%) 5 (21.7%) 10 (20.4%) 0.334
 Chemotherapy protocol 
SJXIIIB 6 (23.1%) 8 (34.8%) 14 (28.6%)
SJXV 8 (30.8%) 4 (17.4%) 12 (24.5%)
BFM90 6 (23.1%) 4 (17.4%) 10 (20.4%)
7+3+2 3 (11.5%) 2 (8.7%) 5 (10.2%)
7+3 0 (0%) 3 (13%) 3 (6.1%)
ADE 3 (11.5%) 2 (8.7%) 5 (10.2%) 0.442
 Oral hygiene 
Excellent 0 (0%) 0 (0%) 0 (0%)
Regular 9 (34.6%) 8 (34.8%) 17 (34.7%)
Deficient 17 (65.4%) 15 (65.2%) 32 (65.3%) 0.990
The data are shown as simple frequency and percentage (%) or mean ± standard deviation
P value according to Fisher’s exact, X2 (sex) or Student’s t test.
Pre-B ALL, Pre B acute lymphoblastic leukemia; AML M0, acute myeloblastic leukemia M0; AML M3, acute myeloblastic leukemia M3; Pro 
B ALL, Pro B acute lymphoblastic leukemia; ALL M2, acute lymphoblastic leukemia M2; Biphenotypic ALL, acute lymphoblastic leukemia 
biphenotypic; SJXIIIB, St. Jude Children's Research Hospital, Total therapy XIIIB chemotherapy protocol; SJXV, St. Jude Children's Research 
Hospital, Total therapy XV chemotherapy protocol; BFM90, Berlin-Frankfurt-Munster-90 chemotherapy protocol; ADE, Ara C-Daunorubicin-
Etoposide chemotherapy protocol.
Table 2: Demographic and clinical characteristics of the participants at the beginning of the study.
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Fig. 1: Flowchart of patients who participated in the study.
Characteristic Control group Experimental group Both groups P value
Number 26 23 49
Days with OM during follow-up 14.2 ± 21.1 5.1 ± 11.2 9.9 ± 17.6 0.072
OM during follow-up
With Oropharyngeal mucositis 12 (46.2%) 6 (26.1%) 18 (36.7%)
Without Oropharyngeal mucositis 14 (53.8%) 17 (73.9%) 31 (63.3%) 0.146
The data are shown as the count (%) or mean ± standard deviation;P value according to the X2 or Student’s t test.
Table 3: Clinical characteristics of study participants during follow-up.
Characteristic β coeff. (95% CI)  P value 
 Sex 
 Male 1.00
 Female 1.51 (0.58, 2.44) 0.002*
 Age, years 
<12 1.00
≥12 0.26 (-0.49, 1.02) 0.498
 Neutropenia 
With neutropenia (>1500/μL) 1.00
Without neutropenia (<1500/μL) 0.19 (-0.64, 1.01) 0.657
 Diagnosis 
 Myeloblastic leukemia 1.00
 Lymphoblastic leukemia 1.37 (-0.17, 2.9) 0.081
 Chemotherapy protocol 
SJXIIIB, SJXV and BFM90 1.00
7+3+2, 7+3 and ADE -1.5 (-2.97, -0.03) 0.046*
 Use of methotrexate 
 No 1.00
 Yes 0.35 (-0.55, 1.24) 0.449
 Oral hygiene 
 Regular and excellent 1.00
 Deficient 0.77 (-0.02, 1.56) 0.055
 Treatment group 
 Control group 1.00
 Experimental group -2.03 (-3.05, -1.01) <0.001*
β coeff: adjusted β regression coefficient, 95% CI: 95% confidence interval 
SJXIIIB, St. Jude Children’s Research Hospital, Total therapy XIIIB chemotherapy protocol; SJXV, St. 
Jude Children’s Research Hospital, Total therapy XV chemotherapy protocol; BFM90, Berlin-Frankfurt-
Munster-90 chemotherapy protocol; ADE, Ara C-Daunorubicin-Etoposide chemotherapy protocol.
Table 4: Multivariate analysis using negative binomial regression.
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Discussion
The results of this study demonstrate that zinc reduces 
OM severity (both in terms of pain and duration of dis-
order) in pediatric patients with leukemia undergoing 
chemotherapy; however, no significant difference was 
found in OM incidence between the experimental and 
control groups. Minimal requirements for children var-
ied between 10 and 15 mg/day. We decided to implement 
for therapeutic purposes 50-mg zinc gluconate, equiva-
lent to 7 mg of elemental zinc, a dose similar to that 
recommended in children. Furthermore, there are a few 
studies done on children that used zinc gluconate to de-
crease the effects of OM; most of the studies have been 
carried out with zinc sulfate in adults and considering 
that the desired effect was obtained with doses of 150mg/
day, we considered a third of the dose for this study.
Shuai et al. described the anti-inflammatory and antiox-
idant effects of zinc, resulting from its ability to elimi-
nate ROS, mediate the expression of COX-2 and inhibit 
the release of PGE2 (11), which may reduce mucotoxic-
ity and explain why patients in this and other studies 
have benefited from zinc use (18).
Rambod et al. administered zinc sulfate (220 mg daily) 
to 44 leukemic adults undergoing chemotherapy and 
observed a difference in OM incidence between the ex-
perimental and control groups at 25.0% and 54.2% re-
spectively (p = 0.01) (23). In comparison, in the present 
study, although there was also a lower incidence of OM 
in the group that took zinc (46.2% vs. 26.1%), the dif-
ference was not significant (p = 0.146). However, with 
respect to the number of days with OM, the time was 
shorter for the experimental group than for the control 
group (5.1 ± 11.21 vs. 14.2 ± 21.1, p = 0.072), which is 
consistent with the findings of Arbidi et al., who de-
scribed that OM recovery was shorter in the zinc group 
than in a placebo group, but the difference was not sig-
nificant (p = 0.13) (17).
Notably, other studies have not demonstrated the pos-
sible benefit of the use of zinc for countering OM. Man-
souri et al. administered 440 mg of zinc sulfate daily 
(versus placebo to the control group) to blood cancer pa-
tients over 15 years of age undergoing HSCT and found 
no reduction in severity, differences in the day of onset 
and duration of OM in the experimental group (p >0.05) 
(18). Similarly, Tian et al. reported that zinc sulfate de-
creased neither the incidence (RR = 0.52; 95% CI: 0.17-
11.64) nor the grade of OM due to chemotherapy (RR = 
0.62, 95% CI: 0.11-3.56; RR = 0.70, 95% CI: 0.29-1.71), 
and that it was also not associated with pain reduction, 
late onset, decreased adverse events or a better quality 
of life compared to controls (3). Unlike these studies, a 
multivariate analysis of our data showed that the experi-
mental group had, on average, 2 less days with OM (p 
= 0.001) from detection until epithelial recovery (beta 
coeff. -2.03; 95% CI: -3.05, -1.01, p <0.001) compared to 
the control group. The lack of consistency between the 
different studies was also illustrated by Chaytana et al. 
in a systematic review. They reported that 8 out of 10 
studies favored zinc over placebo, and when performing 
the meta-analysis, they found an overall effect size of 
-0.89 (95% CI: -1.08, -0.70, p <0.00001) for the different 
zinc supplements used (9).
Another characteristic evaluated in our population was 
oral pain, with the experimental group having a low-
er mean score than the control group (F = 11.12, p = 
0.0009), which is consistent with the findings of Ram-
bod et al., who described a significant difference in the 
mean score for the subjective evaluation of OM (lesions, 
erythema, edema, pain and dysphagia) (F = 5.79, p = 
0.01) and in the mean score on the WHO OM scale (F = 
7.83, p = 0.007) (23).
Our data showed that the highest pain scores for the 
control group were found between days 15 and 30 
(weeks 3 and 5) and at days 45 to 48, almost at the end 
of follow-up (weeks 6 and 7), in the experimental group. 
Fig. 2: Mean score on the WHO OM scale by allocation group during 
the evaluation.
Fig. 3: Mean pain score obtained using a visual analog scale, at the 
different days after enrollment, for each group.
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Similarly, Ribeira et al. reported, in a descriptive study 
of children with acute leukemia undergoing chemother-
apy, that pain, mainly upon swallowing, had a greater 
frequency starting at week 8 (5). The OM scores were 
higher for both groups during the start of the consolida-
tion phase—a finding partially consistent with the re-
sults reported by Curra et al. That is, OM did not occur 
during the induction of leukemia treatment but rather in 
the consolidation phase in 6.1% and in the maintenance 
phase in 8.2% (24) of the participants.
In this study, the chemotherapy protocols—7+3+2, 7+3 
and ADE—used to treat AML were those that on aver-
age were associated with 1.5 less days with OM (beta 
coeff. -1.5; 95% CI: -2.97, -0.03, p = 0.046) compared 
with other protocols (SJXIIIB, SJXV and BFM90), 
which included methotrexate, cytarabine, 6-mercapto-
purine, etoposide, daunorubicin and vincristine, some 
of which have been described as cytotoxic and highly 
associated with OM (25). Bishop et al. described that 
daunorubicin and etoposide led to the development of 
severe OM in 26% of patients who were more than 55 
years old with acute nonlymphocytic leukemia (26).
In the present study, we tried to avoid interrupting the 
course of chemotherapy due to oral manifestations so 
that all patients with caries were treated before and dur-
ing chemotherapy. Additionally, because no adverse 
clinical reactions to zinc were observed (rashes, vomit-
ing, nausea not associated with chemotherapy), no side 
effects were monitored via blood analysis. Besides this 
observation, patients received chemotherapy during the 
intervention. Chemotherapy generates hemoglobin, leu-
kocites, platelet changes, as well as, in a fewer degree, 
renal and hepatic transitory changes. This is the reason 
we decide not to report this information. The major lim-
itations included the small sample size, blinding of par-
ticipants was not carried out, and no placebo was used 
in the control group. Children with acute lymphoblastic 
leukemia during their treatment received steroids and 
more than eight chemotherapeutic agents. We consid-
ered that even if placebo usually does not provoke ad-
verse events, the placebo is generally composed of sug-
ar and secondary diabetes by steroid/L-asparaginasa is 
an important risk in these patients.
We also acknowledge the probable masking of pain due 
to the prescription of intravenous analgesics to decrease 
the pain due to routine medical procedures (venous ca-
nalization, bone marrow aspirates, placement of venous 
catheter, among others) that could decrease the symp-
tomatology of the pain caused by OM, together with the 
application of the philaphelphia solution to control local 
pain. In this study, there was no need to indicate an opi-
oid analgesic, nor was there any need to use a nasogastric 
tube, since OM grade 4 did not occur in either of the two 
groups; there were also no bacteremia due to OM. The 
analgesic doses were adjusted at the discretion of the 
treating physician. We reported three participants’ fol-
low-up losses due to voluntary discharge and two due to 
death, owing to systematic complications due to cancer.
This study, designed to evaluate the effect of zinc on 
chemotherapy-induced OM in pediatric patients with 
acute leukemia, showed a reduction in OM severity and 
duration and associated pain; however, a larger sample 
size is needed to confirm the beneficial effects of this 
trace element. Initially, we worked with a sample size 
calculated with the formula to compare two proportions, 
according to the study by Cheng et al. (20), for a differ-
ence of 50% between the experimental group and the 
control group. We estimated 38 patients per group and 
made an intermediate analysis and significative differ-
ences were obtained, so we decided to stop recruitment.
Although it was not the main objective of the study, 
Kaplan-Meier overall survival estimates among groups 
was calculated. The overall survival was 100% (26/26) 
in the control group and 88.8% (23/25) in the experimen-
tal group. In the cause of the two deaths was not related 
to sepsis nor OM. Moreover, Kaplan-Meier survival es-
timates were not statistically significant among groups.
The treatment of a child or adolescent with cancer in-
cludes many drugs, complications and symptoms typi-
cal of the disease; therefore, it is difficult to conduct a 
study without confounders. There are not enough stud-
ies, in the context of children that describe the maxi-
mum dose of zinc and the optimal time of administra-
tion during oncological treatment to achieve clinical 
effectiveness in preventing or reducing OM severity. 
The great variety of studies that describe presenta-
tions, age groups and hematological conditions place 
zinc as an adjuvant in the prevention and treatment of 
OM with moderate evidence; however, because OM is a 
frequent complication that often interrupts oncological 
treatment, any therapy that presents significant clinical 
benefits without adverse effects should be implemented.
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